ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
Strong cash position at year-end 2025: $33.3 million (€28.4 million) CNS (Vafidemstat) Appointed renowned Rolando Gutierrez-Esteinou, M.D. as new CMO for CNS Preparing protocol resubmission to incorporate FDA guidance on Phase III PORTICO-2 trial in …